Advertising

Merck & Company

MRK-N

NYSE:MRK

71.93
0.25 (0.35%)
Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American pharmaceutical company and one of the largest pharmaceutical companies in the world.
More at Wikipedia

Analysis and Opinions about MRK-N

Signal
Opinion
Expert
Chart
BUY
BUY
May 20, 2021

MRK vs. ABT Both are great companies. ABT is the leading supplier of glasswork to the medical industry. Merck has incredible products as a global pharmaceutical company. You could buy either one.

Show full opinionHide full opinion

MRK vs. ABT Both are great companies. ABT is the leading supplier of glasswork to the medical industry. Merck has incredible products as a global pharmaceutical company. You could buy either one.

Bruce Murray
Price
$79.780
Owned
Unknown
WATCH
WATCH
April 30, 2021
They have an analyst meeting on Monday. Watch that, because they reported ugly numbers earlier this week.
Show full opinionHide full opinion
Merck & Company (MRK-N)
April 30, 2021
They have an analyst meeting on Monday. Watch that, because they reported ugly numbers earlier this week.
Jim Cramer - Mad Money
Price
$74.500
Owned
Unknown
TOP PICK
TOP PICK
March 18, 2021
Stockchase Research Editor: Michael O'Reilly MRK returns as a TOP PICK. Trading at 17 times earnings, compared with its peers at 40x it is good value here. It pays an excellent dividend, backed by payout ratio of only 50% of cash flow. We would buy it here with a stop-loss at $65, looking to achieve $96 -- upside potential of 23%. Yield 3.36% (Analysts’ price target is $96.33)
Show full opinionHide full opinion
Merck & Company (MRK-N)
March 18, 2021
Stockchase Research Editor: Michael O'Reilly MRK returns as a TOP PICK. Trading at 17 times earnings, compared with its peers at 40x it is good value here. It pays an excellent dividend, backed by payout ratio of only 50% of cash flow. We would buy it here with a stop-loss at $65, looking to achieve $96 -- upside potential of 23%. Yield 3.36% (Analysts’ price target is $96.33)
DON'T BUY
DON'T BUY
February 8, 2021

Like BMY, nobody wants these drug stocks now. The reopening trade is a headwind. The economy will reopen, so investors think they don't need a drink stock, no matter how well that stock is performing.

Show full opinionHide full opinion
Merck & Company (MRK-N)
February 8, 2021

Like BMY, nobody wants these drug stocks now. The reopening trade is a headwind. The economy will reopen, so investors think they don't need a drink stock, no matter how well that stock is performing.

Jim Cramer - Mad Money
Price
$75.040
Owned
Unknown
BUY
BUY
January 19, 2021
It's a bellwhether pharamceutical, but he doesn't like this space because drug patents constantly expire under given patent law. Merck is getting interesting, partially because of valuation around 12x PE. Also, because their franchise drug is an oncology drug that doesn't come off patent until 2026. It pays a good dividend. It's become more interesting because the PE has declined.
Show full opinionHide full opinion
Merck & Company (MRK-N)
January 19, 2021
It's a bellwhether pharamceutical, but he doesn't like this space because drug patents constantly expire under given patent law. Merck is getting interesting, partially because of valuation around 12x PE. Also, because their franchise drug is an oncology drug that doesn't come off patent until 2026. It pays a good dividend. It's become more interesting because the PE has declined.
Gordon Reid
Price
$82.970
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
January 13, 2021
(A Top Pick Jan 30/20, Down 1%) Still likes. Continues to buy. Discount to other big pharma. Cancer drugs are very high margin. Pandemic has spurred pharma sales. Will benefit as life returns to normal. Yield is 3.1%.
Show full opinionHide full opinion
Merck & Company (MRK-N)
January 13, 2021
(A Top Pick Jan 30/20, Down 1%) Still likes. Continues to buy. Discount to other big pharma. Cancer drugs are very high margin. Pandemic has spurred pharma sales. Will benefit as life returns to normal. Yield is 3.1%.
Stan Wong
Price
$82.405
Owned
Yes
SELL
SELL
December 16, 2020

All big pharmas have been treading water. Patent legislation has left them with a leaky boat. He's gravitated toward the bio-pharmas. His favourite in that space is AbbVie, as it's good on fundamentals and financials, inexpensive, very fine dividend, great cashflow generator.

Show full opinionHide full opinion
Merck & Company (MRK-N)
December 16, 2020

All big pharmas have been treading water. Patent legislation has left them with a leaky boat. He's gravitated toward the bio-pharmas. His favourite in that space is AbbVie, as it's good on fundamentals and financials, inexpensive, very fine dividend, great cashflow generator.

Gordon Reid
Price
$80.000
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
October 29, 2020
(A Top Pick Sep 29/20, Down 5.9%)Stockchase Research Editor: Michael O'Reilly We are recommending to cover MRK as it has violated our stop-loss. We are going to look for better opportunities.
Show full opinionHide full opinion
Merck & Company (MRK-N)
October 29, 2020
(A Top Pick Sep 29/20, Down 5.9%)Stockchase Research Editor: Michael O'Reilly We are recommending to cover MRK as it has violated our stop-loss. We are going to look for better opportunities.
PAST TOP PICK
PAST TOP PICK
October 21, 2020
(A Top Pick Oct 24/19, Down 2%) Healthcare is a resilient sector, not cyclical. Strong in oncology space. Pandemic has crimped pharma sales, especially from hospitals. Shares are cheap, 9% earnings growth rate, dividend over 3%.
Show full opinionHide full opinion
Merck & Company (MRK-N)
October 21, 2020
(A Top Pick Oct 24/19, Down 2%) Healthcare is a resilient sector, not cyclical. Strong in oncology space. Pandemic has crimped pharma sales, especially from hospitals. Shares are cheap, 9% earnings growth rate, dividend over 3%.
Stan Wong
Price
$78.480
Owned
Yes
PAST TOP PICK
PAST TOP PICK
October 20, 2020
(A Top Pick Jul 17/19, Down 4%) Still likes this diversified large-cap biopharma. Has a great diabetes franchise, though little growth, but they rely on an immunotherapy franchise (a cancer treatment)--they've done great execution here over the past 6 years.
Show full opinionHide full opinion
Merck & Company (MRK-N)
October 20, 2020
(A Top Pick Jul 17/19, Down 4%) Still likes this diversified large-cap biopharma. Has a great diabetes franchise, though little growth, but they rely on an immunotherapy franchise (a cancer treatment)--they've done great execution here over the past 6 years.
Paul MacDonald
Price
$78.540
Owned
Yes
TOP PICK
TOP PICK
September 29, 2020
Stockchase Research Editor: Michael O'Reilly MRK is one of the largest pharma companies in the world. It trades at a 13 PE compared to 22 PE for the S&P500. The pandemic has slowed some elective procedures, and that has slowed sales in the latest quarter by about 9%. However, management still opted to raise its 2020 guidance showing confidence that things should improve for the balance of the year. The company also has three drugs moving through various COVID-19 vaccine test trials. It pays a good yield, backed by a 58% payout ratio. We would buy this with an upper target towards $96 as the first objective and use $77 as a stop-loss. Yield 2.95% (Analysts’ price target is $95.94)
Show full opinionHide full opinion
Merck & Company (MRK-N)
September 29, 2020
Stockchase Research Editor: Michael O'Reilly MRK is one of the largest pharma companies in the world. It trades at a 13 PE compared to 22 PE for the S&P500. The pandemic has slowed some elective procedures, and that has slowed sales in the latest quarter by about 9%. However, management still opted to raise its 2020 guidance showing confidence that things should improve for the balance of the year. The company also has three drugs moving through various COVID-19 vaccine test trials. It pays a good yield, backed by a 58% payout ratio. We would buy this with an upper target towards $96 as the first objective and use $77 as a stop-loss. Yield 2.95% (Analysts’ price target is $95.94)
PAST TOP PICK
PAST TOP PICK
August 26, 2020
(A Top Pick Sep 11/19, Up 6%) In his favourite sectors of bio and pharma. Strong in oncology. Diversified pipeline. Trading at a bit of a discount, 15x forward earnings, 2.9% dividend. Compelling story for the dividend and growth in the sector.
Show full opinionHide full opinion
Merck & Company (MRK-N)
August 26, 2020
(A Top Pick Sep 11/19, Up 6%) In his favourite sectors of bio and pharma. Strong in oncology. Diversified pipeline. Trading at a bit of a discount, 15x forward earnings, 2.9% dividend. Compelling story for the dividend and growth in the sector.
Stan Wong
Price
$85.440
Owned
Yes
HOLD
HOLD
July 9, 2020
You'd need to have a Democratic sweep in the upcoming election to have an effect on Wall St. Has a 3.2% yield. Great pipeline of drugs. 8% growth rate. Lagged healthcare the last little while, as most money has gone to Covid treatments. Continues to hold.
Show full opinionHide full opinion
You'd need to have a Democratic sweep in the upcoming election to have an effect on Wall St. Has a 3.2% yield. Great pipeline of drugs. 8% growth rate. Lagged healthcare the last little while, as most money has gone to Covid treatments. Continues to hold.
Stan Wong
Price
$76.750
Owned
Yes
DON'T BUY
DON'T BUY
June 17, 2020
An Act in the US back in the early 1980's introduced the end of patents with drugs. Patent expiration opened the door for generics. MRK has become the most successful pharma company and has a big patent coming due soon. He would tend to move towards the bio-pharma space instead.
Show full opinionHide full opinion
An Act in the US back in the early 1980's introduced the end of patents with drugs. Patent expiration opened the door for generics. MRK has become the most successful pharma company and has a big patent coming due soon. He would tend to move towards the bio-pharma space instead.
Gordon Reid
Price
$76.320
Owned
Yes
TOP PICK
TOP PICK
May 8, 2020
A Top 100 S&P company, trading in US dollars. His model price is $133.28. A good pullback in price -- good value here. He sees supply chains coming back in health back to US companies. Yield 3.2% (Analysts’ price target is $93.68)
Show full opinionHide full opinion
A Top 100 S&P company, trading in US dollars. His model price is $133.28. A good pullback in price -- good value here. He sees supply chains coming back in health back to US companies. Yield 3.2% (Analysts’ price target is $93.68)
Brian Acker, CA
Price
$76.220
Owned
Yes
Showing 1 to 15 of 202 entries

Merck & Company(MRK-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 6

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 8

Stockchase rating for Merck & Company is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Merck & Company(MRK-N) Frequently Asked Questions

What is Merck & Company stock symbol?

Merck & Company is a American stock, trading under the symbol MRK-N on the New York Stock Exchange (MRK). It is usually referred to as NYSE:MRK or MRK-N

Is Merck & Company a buy or a sell?

In the last year, 8 stock analysts published opinions about MRK-N. 6 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Merck & Company.

Is Merck & Company a good investment or a top pick?

Merck & Company was recommended as a Top Pick by Bruce Murray on 2021-05-20. Read the latest stock experts ratings for Merck & Company.

Why is Merck & Company stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Merck & Company worth watching?

8 stock analysts on Stockchase covered Merck & Company In the last year. It is a trending stock that is worth watching.

What is Merck & Company stock price?

On 2021-09-20, Merck & Company (MRK-N) stock closed at a price of $71.93.